Aurinia Pharmaceuticals (AUPH) said Wednesday evening that an experimental medicine used to treat patients with lupus nephritis, an autoimmune kidney disease, achieved all primary and secondary efficacy goals in a late-stage clinical trial.
The drugmaker, headquartered near Vancouver, Canada, expects to submit a marketing application to the U.S. Food and Drug Administration in the first half of next year.
Aurinia’s stock price more than doubled in value to $17.30 per share in after-hours trading.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect